背景:本研究旨在评估术前、术前和术后玻璃体腔注射康柏西普(IVC)对重度增生性糖尿病视网膜病变(PDR)的影响。
方法:这是一个前瞻性的,比较和随机研究。本研究共纳入84例因严重PDR而接受玻璃体切除术的患者。将患者随机分为对照组(41只眼)和实验组(43只眼)。实验组患者在手术前和手术后接受辅助IVC注射,而对照组患者仅接受术前IVC注射。术后玻璃体出血(POVH)的发生率,确定最佳矫正视力(BCVA)和中央视网膜厚度(CRT)。
结果:两组早期POVH的发生率有显著差异,但在3个月和6个月时,组间没有观察到显著差异。在实验组中,与对照组相比,术后1个月BCVA显著改善(p0.019).组间术后3个月和6个月的平均BCVA没有显着差异(p0.063和0.082)。术后1个月和3个月,实验组的CRT明显低于对照组(p0.037和0.041),但6个月时无显著差异(p0.894)。
结论:在手术结束时额外注射IVC可改善严重PDR手术后早期的POVH和BCVA,但是这种好处在6个月时就不存在了。需要进一步的研究来研究玻璃体切除术结束时IVC的效果。
背景:chictr.org.cn标识符:ChiCTR2200060735。追溯登记,注册日期:2022年6月9日。
BACKGROUND: This
study aimed to evaluate the effect of pre-operative versus pre-operative plus post-operative intravitreal conbercept (IVC) injection on severe proliferative diabetic retinopathy (PDR).
METHODS: This was a prospective, comparative and randomised
study. A total of 84 patients who underwent vitrectomy for severe PDR were included in this
study. Patients were randomly divided into control (41 eyes) and experiment (43 eyes) groups. Patients in the experiment group received adjunctive pre-operative and post-operative IVC injection, whereas patients in the control group only received pre-operative IVC injection. The incidence of post-operative vitreous haemorrhage (POVH), best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were determined.
RESULTS: The incidence of early POVH was significantly different between the two groups, but no significant difference was observed between groups at 3 and 6 months. In the experiment group, the BCVA was significantly improved 1 month after surgery when compared with the control group (p 0.019). There was no marked difference in the mean post-operative BCVA at 3 and 6 months between groups (p 0.063 and 0.082). CRT was significantly lower in the experiment group than in the control group at 1 and 3 months after surgery (p 0.037 and 0.041), but there was no significant difference at 6 months (p 0.894).
CONCLUSIONS: Additional IVC injected at the end of surgery improves the POVH and BCVA at the early stage after surgery in severe PDR, but this benefit is absent at 6 months. Further studies are needed to investigate the effect of IVC at the end of vitrectomy.
BACKGROUND: chictr.org.cn identifier: ChiCTR2200060735. Retrospectively registered, register date: 9 June 2022.